Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Net Cash Provided by (Used in) Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

Celldex Therapeutics, Inc. Net Cash Provided by (Used in) Continuing Operations

Celldex Therapeutics, Inc. (CLDX) reported Net Cash Provided by (Used in) Continuing Operations of $94.15 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-29.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2015-04-29

  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for the quarter ending 2015-03-31 was $94.15M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-12-31 was -$4.50M, a 102.91% decline year-over-year.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-09-30 was -$8.27M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for the quarter ending 2014-06-30 was -$16.11M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for fiscal 2014 was -$141.38M, a 197.84% decline from fiscal 2013.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for fiscal 2013 was $144.50M, a 1011.75% increase from fiscal 2012.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for fiscal 2012 was $13.00M.
  • Celldex Therapeutics, Inc. net cash provided by (used in) continuing operations for fiscal 2011 was -$9.39M.
Period endNet Cash Provided by (Used in) Continuing Operations 3 monthNet Cash Provided by (Used in) Continuing Operations 6 monthNet Cash Provided by (Used in) Continuing Operations 9 monthNet Cash Provided by (Used in) Continuing Operations 12 month
2015-03-31$94.15M
10-Q · filed 2015-04-29
$89.64M
derived: sum of 2 quarters · filed 2015-04-29
$81.37M
derived: sum of 3 quarters · filed 2015-04-29
$65.27M
derived: sum of 4 quarters · filed 2015-04-29
2014-12-31-$4.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
-$12.78M
derived: sum of 2 quarters · filed 2015-02-24
-$28.88M
derived: sum of 3 quarters · filed 2015-02-24
-$141.38M
10-K · filed 2015-02-24
2014-09-30-$8.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05
-$24.38M
derived: sum of 2 quarters · filed 2014-11-05
-$136.88M
10-Q · filed 2014-11-05
$17.90M
derived: sum of 4 quarters · filed 2015-04-29
2014-06-30-$16.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$128.60M
10-Q · filed 2014-08-07
$26.17M
derived: sum of 3 quarters · filed 2015-04-29
$14.90M
derived: sum of 4 quarters · filed 2015-04-29
2014-03-31-$112.50M
10-Q · filed 2015-04-29
$42.28M
derived: sum of 2 quarters · filed 2015-04-29
$31.00M
derived: sum of 3 quarters · filed 2015-04-29
-$18.73M
derived: sum of 4 quarters · filed 2015-04-29
2013-12-31$154.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
$143.50M
derived: sum of 2 quarters · filed 2015-02-24
$93.78M
derived: sum of 3 quarters · filed 2015-02-24
$144.50M
10-K · filed 2015-02-24
2013-09-30-$11.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05
-$61.00M
derived: sum of 2 quarters · filed 2014-11-05
-$10.27M
10-Q · filed 2014-11-05
-$8.56M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30-$49.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$1.00M
10-Q · filed 2014-08-07
$2.71M
derived: sum of 3 quarters · filed 2015-02-24
$7.34M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31$50.73M
10-Q · filed 2014-05-01
$52.44M
derived: sum of 2 quarters · filed 2015-02-24
$57.06M
derived: sum of 3 quarters · filed 2015-02-24
$52.87M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
$6.33M
derived: sum of 2 quarters · filed 2015-02-24
$2.14M
derived: sum of 3 quarters · filed 2015-02-24
$13.00M
10-K · filed 2015-02-24
2012-09-30$4.62M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$432.00K
derived: sum of 2 quarters · filed 2013-11-08
$11.29M
10-Q · filed 2013-11-08
$10.09M
derived: sum of 4 quarters · filed 2014-03-03
2012-06-30-$4.19M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
$6.66M
10-Q · filed 2013-08-06
$5.47M
derived: sum of 3 quarters · filed 2014-03-03
$7.73M
derived: sum of 4 quarters · filed 2014-03-03
2012-03-31$10.86M
10-Q · filed 2013-05-03
$9.66M
derived: sum of 2 quarters · filed 2014-03-03
$11.93M
derived: sum of 3 quarters · filed 2014-03-03
$12.62M
derived: sum of 4 quarters · filed 2014-03-03
2011-12-31-$1.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$1.07M
derived: sum of 2 quarters · filed 2014-03-03
$1.76M
derived: sum of 3 quarters · filed 2014-03-03
-$9.39M
10-K · filed 2014-03-03
2011-09-30$2.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02
$2.96M
derived: sum of 2 quarters · filed 2012-11-02
-$8.19M
10-Q · filed 2012-11-02
$3.27M
derived: sum of 4 quarters · filed 2013-03-08
2011-06-30$690.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$10.46M
10-Q · filed 2012-08-09
$1.00M
derived: sum of 3 quarters · filed 2013-03-08
2011-03-31-$11.15M
10-Q · filed 2012-05-04
$312.00K
derived: sum of 2 quarters · filed 2013-03-08
2010-12-31$11.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08
-$35.72M
10-K · filed 2013-03-08
2010-09-30-$47.17M
10-Q · filed 2011-11-03
2009-12-31$12.74M
10-K · filed 2012-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93